Analyzing CAR T Cell Activity by Live Cell Imaging and Real Time Impedance
A Real-Time Assay for CAR T Cell Potency
During chimeric antigen receptor (CAR) optimization, scientists use biochemical and biophysical assays for studying critical quality attributes, such as antigen affinity or cytokine profiles. However, these assays do not necessarily correlate with cancer-killing efficacy. To compare different CAR constructs and to identify unwanted behavior such as tonic signaling, CAR function should be evaluated within the complex milieu of the immune synapse, using bona fide cancer cell killing as the readout. Release assays are typically used for this purpose, however, they require long hands-on times and provide only end-point data. The Agilent xCELLigence RTCA eSight is an alternative solution for continuously monitoring CAR T cell-mediated killing of cancer cells over the course of multiple days.
Download this app note from ACEA Biosciences, a part of Agilent Technologies, to learn
- How to investigate real-time potency of CAR T cells with the xCELLigence RTCA eSight
- How the assay reduces hands on work time compared to release assays
- Why coupling real-time impedance monitoring with highly specific live cell imaging readouts better characterizes CAR T-cell killing efficacy
